JP2011153125A - Autonomic control agent containing pseudo-leaf of asparagus as active ingredient - Google Patents
Autonomic control agent containing pseudo-leaf of asparagus as active ingredient Download PDFInfo
- Publication number
- JP2011153125A JP2011153125A JP2010183967A JP2010183967A JP2011153125A JP 2011153125 A JP2011153125 A JP 2011153125A JP 2010183967 A JP2010183967 A JP 2010183967A JP 2010183967 A JP2010183967 A JP 2010183967A JP 2011153125 A JP2011153125 A JP 2011153125A
- Authority
- JP
- Japan
- Prior art keywords
- asparagus
- autonomic
- sleep
- pseudo
- leaf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000005340 Asparagus officinalis Nutrition 0.000 title claims abstract description 71
- 239000004480 active ingredient Substances 0.000 title claims abstract description 20
- 230000002567 autonomic effect Effects 0.000 title claims abstract description 15
- 244000003416 Asparagus officinalis Species 0.000 title abstract description 67
- 235000013305 food Nutrition 0.000 claims abstract description 34
- 239000000463 material Substances 0.000 claims abstract description 24
- 235000013376 functional food Nutrition 0.000 claims abstract description 13
- 206010003591 Ataxia Diseases 0.000 claims abstract description 7
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 claims description 30
- 230000006872 improvement Effects 0.000 claims description 16
- 230000002265 prevention Effects 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000003449 preventive effect Effects 0.000 claims description 7
- 241001317099 Dystaxia Species 0.000 claims description 3
- 241000234427 Asparagus Species 0.000 claims 5
- 210000000467 autonomic pathway Anatomy 0.000 abstract description 34
- 239000000843 powder Substances 0.000 abstract description 24
- 238000000034 method Methods 0.000 abstract description 11
- 238000001035 drying Methods 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 2
- 238000010298 pulverizing process Methods 0.000 abstract description 2
- 238000000605 extraction Methods 0.000 abstract 1
- 230000008014 freezing Effects 0.000 abstract 1
- 238000007710 freezing Methods 0.000 abstract 1
- 238000000265 homogenisation Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 description 25
- 208000024891 symptom Diseases 0.000 description 17
- 230000008035 nerve activity Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 239000003814 drug Substances 0.000 description 13
- 230000002618 waking effect Effects 0.000 description 10
- 210000005037 parasympathetic nerve Anatomy 0.000 description 9
- 230000002889 sympathetic effect Effects 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 235000021266 loss of appetite Nutrition 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 230000004596 appetite loss Effects 0.000 description 7
- 210000003403 autonomic nervous system Anatomy 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 208000019017 loss of appetite Diseases 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- AHOUBRCZNHFOSL-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine Chemical compound C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 6
- 208000019901 Anxiety disease Diseases 0.000 description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 6
- 230000036506 anxiety Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 206010022437 insomnia Diseases 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 235000014214 soft drink Nutrition 0.000 description 6
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 5
- 244000269722 Thea sinensis Species 0.000 description 5
- 235000019789 appetite Nutrition 0.000 description 5
- 230000036528 appetite Effects 0.000 description 5
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 5
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 5
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 5
- 235000005493 rutin Nutrition 0.000 description 5
- 229960004555 rutoside Drugs 0.000 description 5
- 230000035807 sensation Effects 0.000 description 5
- 235000019615 sensations Nutrition 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000013616 tea Nutrition 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 240000008620 Fagopyrum esculentum Species 0.000 description 3
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229960005183 paroxetine hydrochloride Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000445939 Asparagus africanus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000033830 Hot Flashes Diseases 0.000 description 2
- 206010060800 Hot flush Diseases 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- 241000237502 Ostreidae Species 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- KGEKLUUHTZCSIP-HOSYDEDBSA-N [(1s,4s,6r)-1,7,7-trimethyl-6-bicyclo[2.2.1]heptanyl] acetate Chemical compound C1C[C@]2(C)[C@H](OC(=O)C)C[C@H]1C2(C)C KGEKLUUHTZCSIP-HOSYDEDBSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940036969 cloxazolam 1 mg Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000008450 motivation Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000020636 oyster Nutrition 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000013322 soy milk Nutrition 0.000 description 2
- 235000011496 sports drink Nutrition 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000605422 Asparagus asparagoides Species 0.000 description 1
- 241000432767 Asparagus setaceus Species 0.000 description 1
- UMSGKTJDUHERQW-UHFFFAOYSA-N Brotizolam Chemical compound C1=2C=C(Br)SC=2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl UMSGKTJDUHERQW-UHFFFAOYSA-N 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 235000018958 Gardenia augusta Nutrition 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- XNCDYJFPRPDERF-PBCQUBLHSA-N Milnacipran hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1C[NH3+] XNCDYJFPRPDERF-PBCQUBLHSA-N 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041052 Sluggishness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042209 Stress Diseases 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000186514 Warburgia ugandensis Species 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940125713 antianxiety drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940115397 bornyl acetate Drugs 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229960003051 brotizolam Drugs 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000010675 chips/crisps Nutrition 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 229940105039 coconut extract Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940024412 fluvoxamine maleate 25 mg Drugs 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 229960000638 milnacipran hydrochloride Drugs 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 235000019685 rice crackers Nutrition 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 230000036578 sleeping time Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000004071 soot Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- -1 sucrose fatty acid esters Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Abstract
Description
本発明は、アスパラガス擬葉を有効成分とする自律神経調整剤に関し、より詳細には、該アスパラガス擬葉又はその処理物を有効成分とする自律神経調整剤、自律神経失調症の予防又は改善剤、睡眠改善剤、自律神経失調症の予防又は改善用機能性食品又は食品素材、及びアスパラガス擬葉又はその処理物の使用方法に関する。 The present invention relates to an autonomic nerve regulator comprising asparagus pseudo leaves as an active ingredient, more specifically, an autonomic nerve regulator comprising the asparagus pseudo leaves or a processed product thereof as an active ingredient, prevention of autonomic dysfunction or The present invention relates to an improving agent, a sleep improving agent, a functional food or food material for preventing or improving autonomic dysfunction, and a method for using asparagus pseudo leaves or a processed product thereof.
自律神経系は、各種内臓、血管、腺などに広く分布し、付随的に各臓器を調節することにより、外的内的環境に対して合目的に一定の状態homeostasis(ホメオスタシス)を維持する機能を果たしている神経系であり、植物神経系ともいわれている。自律神経系には交感神経系と副交感神経系の2系統があり、自律神経系は両者のバランスによりコントロールされている。すなわち、身体が活動している時は交感神経の活動が優位となり、全身が緊張した状態となる。逆に、副交感神経の活動が優位な時は身体の緊張がとれ、くつろいでいる状態となる。また、ストレスにより自律神経活動の乱れが長期に続くと様々な身体的障害が生じてくることが知られている。自律神経活動の乱れとは、交感神経活動が優位な状態あるいは副交感神経活動が優位な状態を意味するが、特に現代社会においては、交感神経活動の優位な状態が持続することによる健康障害が問題視されている。 The autonomic nervous system is widely distributed in various internal organs, blood vessels, glands, etc., and functions to maintain a certain state homeostasis (homeostasis) for the external internal environment by adjusting each organ concomitantly It is also said to be a plant nervous system. The autonomic nervous system has two systems, a sympathetic nervous system and a parasympathetic nervous system, and the autonomic nervous system is controlled by a balance between the two. That is, when the body is active, sympathetic nerve activity is dominant, and the whole body is in tension. Conversely, when parasympathetic activity predominates, the body becomes tense and relaxed. In addition, it is known that various disabilities occur when disturbance of autonomic nerve activity continues for a long time due to stress. Disturbance of autonomic nervous activity means a state where sympathetic nerve activity is dominant or parasympathetic nerve activity is dominant, but in modern society, health problems due to the persistence of sympathetic nerve activity are a problem. Is being viewed.
交換神経と副交感神経のバランスは、ヒトにおける心の状態とも密接に関連することがわかってきた。たとえばうつ状態では、リラックス時に活動が亢進するはずの副交感神経の活動が低下しているが、快癒すると、リラックス時には副交感神経が優位に働く正常なバランスを取り戻す。また、過度なストレスにさらされると、やはり副交感神経がうまく機能せず、交感神経の活動が亢進を続け、不眠等の体調不良を引き起こすこともわかってきた。他の症状としては、頭痛、めまい、疲労感、ふるえ、四肢冷感、発汗異常、動悸、息切れ、胸部圧迫感、胸痛、食欲不振、胃部膨満感、便秘、下痢など多彩である。近年では、副交感神経活動低下が冠動脈性心疾患や突然死の重要な危険因子である事が指摘されている。自律神経系の機能低下によって起こる様々な愁訴は自律神経失調症と呼ばれ、正常な日常生活の維持向上に著しい悪影響を及ぼす。 The balance between the exchange and parasympathetic nerves has been found to be closely related to the state of the heart in humans. For example, in a depressed state, the parasympathetic nerve activity, which should be increased when relaxed, is reduced, but when healed, the normal balance in which the parasympathetic nerve predominates when restored is restored. It has also been found that when exposed to excessive stress, parasympathetic nerves do not function well, sympathetic nerve activity continues to increase, and poor physical condition such as insomnia occurs. Other symptoms include headache, dizziness, fatigue, tremor, cold limbs, sweating abnormalities, palpitation, shortness of breath, chest tightness, chest pain, loss of appetite, stomach fullness, constipation, and diarrhea. In recent years, it has been pointed out that decreased parasympathetic nerve activity is an important risk factor for coronary heart disease and sudden death. Various complaints caused by a decrease in the function of the autonomic nervous system are called autonomic dysfunction and have a significant adverse effect on the maintenance and improvement of normal daily life.
前記各症状や疾患ごとに対症的に治療が行なわれているのが実状であって、根本的な原因である自律神経活動そのものをコントロールする方法はとられていない。対症療法は一時的にその病態そのものを改善することができるが、服薬を中止すれば再発し、また、服薬を継続していれば、一つの疾患は改善したとしても、根本原因である自律神経の乱れや自律神経活動低下による他の疾患が発症する場合も多い。そこで、根本原因である自律神経活動そのものをコントロールする医薬品あるいは健康食品が求められていた。つまり、何らかの要因により亢進した交感神経活動もしくは副交感神経活動を抑制したり、低下した交感神経活動もしくは副交感神経活動を上昇させることにより、交感神経活動優位な状態、副交感神経活動優位な状態、全体的に自律神経活動が亢進した状態もしくは低下した状態を回復させる作用を有する有効成分化合物、物質又は天然物が得られれば、種々の疾患の予防的観点からも利用価値はきわめて高い。 In reality, treatment is performed symptomatically for each symptom or disease, and a method for controlling the autonomic nerve activity itself, which is the root cause, has not been taken. Symptomatic therapy can temporarily improve the condition itself, but it will recur if you stop taking the drug, and if you continue to take it, the autonomic nerve that is the root cause of the disease may be improved. Many other diseases develop due to disturbances in the body and decreased autonomic nervous activity. Therefore, there has been a demand for pharmaceuticals or health foods that control the autonomic nervous activity itself that is the root cause. In other words, by suppressing sympathetic nerve activity or parasympathetic nerve activity that has been increased for some reason, or by increasing decreased sympathetic nerve activity or parasympathetic nerve activity, a state in which sympathetic nerve activity is dominant, a state in which parasympathetic nerve activity is dominant, overall If an active ingredient compound, substance or natural product having an action of recovering a state in which autonomic nerve activity is enhanced or reduced is obtained, the utility value is extremely high from the viewpoint of preventing various diseases.
従来、自律神経失調症、不安症、うつ病の予防・治療剤に用いる有効成分化合物は種々提案されており、また、天然に由来する物質がヒトには安心感を与え、古くは生薬として多く知られている。動植物に由来するものとしては、薬用ニンジンの粗サポニンを有効成分とする自律神経失調症を伴うストレス症状の回復剤(例えば、特許文献1参照)や、天然素材から通常の方法によって抽出することにより得られるドコサヘキサエン酸及び/又はエイコサペンタエン酸等のn−3系高度不飽和脂肪酸を構成成分として含むリン脂質を有効成分として含有する交感神経の興奮抑制剤(例えば、特許文献2参照)が知られている。 Various active ingredient compounds have been proposed in the past for the prevention and treatment of autonomic dysfunction, anxiety and depression, and naturally derived substances give a sense of security to humans and have been widely used as crude drugs in the past. Are known. As derived from animals and plants, by extracting from a natural material by an ordinary method from a stress symptom-recovering agent associated with autonomic dysfunction, comprising a crude saponin of medicinal carrot as an active ingredient Known sympathetic excitation inhibitors containing phospholipids containing n-3 polyunsaturated fatty acids such as docosahexaenoic acid and / or eicosapentaenoic acid as constituents are known (see, for example, Patent Document 2). ing.
また、テアニン(茶からの抽出物)と、ハーブ、GABA及びパラチノースからなる群より選ばれる1種又は2種以上を含有する抗ストレス及びリラックス用組成物(例えば、特許文献3参照)や、カルノシン及びアンセリンを含む鶏肉抽出物を含有する学習機能向上効果及び抗不安効果を有する機能性食品(例えば、特許文献4参照)や、マツリカ(茉莉花、jasmin sambac)の抽出物、3−メチルオクタノ−4−ラクトン、ボルニルアセテート、及びタイム(thymus vulgaris)の水蒸気蒸留物から選ばれる1種又は2種以上を有効成分とする自律神経調整剤(例えば、特許文献5参照)が知られている。 Further, a composition for anti-stress and relaxation containing one or two or more selected from the group consisting of theanine (an extract from tea) and herbs, GABA and palatinose (for example, see Patent Document 3), carnosine And a functional food having a learning function improving effect and an anxiolytic effect (for example, see Patent Document 4), an extract of pine (jasmin sambac), 3-methyloctano-4- There is known an autonomic nerve regulator comprising one or more selected from lactone, bornyl acetate, and thymus vulgaris steam distillate as active ingredients (see, for example, Patent Document 5).
さらに、リラックス効果がある飲料水としては、硬度が60〜2000の水を含む、リラックス効果を有する飲料水(例えば、特許文献6参照)が知られている。 Furthermore, as drinking water which has a relaxing effect, the drinking water which has a relaxing effect containing the water of hardness 60-2000 (for example, refer patent document 6) is known.
他方、アスパラガスの茎・擬葉を利用した技術としては、グリーンアスパラガスの茎の部分を乾燥、粉砕、焙煎してなるアスパラガスを原料とした粉末茶や、該粉末茶にアスパラガスの擬葉を同様に乾燥、粉砕、焙煎してなる粉末葉茶を配合した配合茶(例えば、特許文献7参照)や、ルチン及び1g乾燥重量あたり少なくとも100mgの糖類を含むアスパラガス(Asparagus)属植物の擬葉組織の乾燥粉末(例えば、特許文献8参照)が知られている。 On the other hand, as a technique using asparagus stems and artificial leaves, powdered tea made from asparagus obtained by drying, pulverizing, and roasting green asparagus stems, or asparagus A blended tea blended with powdered leaf tea obtained by similarly drying, crushing, and roasting artificial leaves (see, for example, Patent Document 7), and Asparagus genus containing rutin and at least 100 mg of sugar per 1 g dry weight A dry powder of a pseudo-leaf tissue of a plant (for example, see Patent Document 8) is known.
一方、アスパラガス擬葉を有効成分とする自律神経調整剤、自律神経失調症の予防又は改善剤、睡眠改善剤等は知られていない。 On the other hand, there are no known autonomic nerve regulators containing asparagus pseudo leaves as active ingredients, preventive or ameliorating agents for autonomic dysfunction, sleep improving agents, and the like.
本発明は、安全かつ効果的に自律神経を調整することができ、自律神経失調症の予防又は改善、睡眠状態を効果的に改善できる自律神経調整剤、自律神経失調症の予防又は改善用機能性食品又は食品素材、前記自律神経調整剤を自律神経失調症の予防又は改善用及び睡眠改善用として食品又は食品素材に含有する使用方法、及び自律神経失調症の予防又は改善用、及び睡眠改善用としての食品又は食品素材の製造における使用を提供する。 The present invention is capable of adjusting an autonomic nerve safely and effectively, preventing or improving autonomic dysfunction, an autonomic nerve adjusting agent capable of effectively improving sleep state, and a function for preventing or improving autonomic dysfunction Food or food material, a method for using the autonomic nerve modifier in food or food material for prevention or improvement of autonomic dysfunction and for sleep improvement, and prevention or improvement of autonomic dysfunction, and sleep improvement Provided for use in the production of food or food ingredients for use.
本発明者らは、アスパラガスの栽培が盛んな北海道で、アスパラガスの収穫後、先端より25cm以下の茎や、成長したグリーンアスパラガスに繁った葉(擬葉)が大量に廃棄されていることに注目し、前記擬葉には、以前からルチンの含有量が多いことが知られてはいたが、さらにアスパラガス擬葉の有効な用途を開発するべく鋭意検討した結果、アスパラガス擬葉又はその処理物を軽度のうつ病と診断された人や、不定愁訴の症状をもつ人、不眠症を訴える人などに投与したところ、前記症状が改善されたことから、さらに研究を進めた結果、自立神経失調症、不眠症など自律神経系統における疾患の予防、改善に有効であることを見出し、本発明を完成するに至った。 In Hokkaido, where asparagus is actively cultivated, the present inventors have discarded a large amount of stems 25 cm or less from the tip and leaves grown on green asparagus (pseudo leaves) after harvesting asparagus. In particular, the pseudo leaves have been known to have a high rutin content for some time, but as a result of intensive studies to develop an effective use of the asparagus pseudo leaves, Or the results of further research since the treated symptoms were administered to people diagnosed with mild depression, those with indefinite complaints, those who reported insomnia, etc. The inventors have found that the present invention is effective in preventing and improving diseases in the autonomic nervous system such as autonomic insufficiency and insomnia, and have completed the present invention.
すなわち、本発明は(1)アスパラガス擬葉を有効成分とすることを特徴とする自律神経調整剤や、(2)アスパラガス擬葉を有効成分とすることを特徴とする自律神経失調症の予防又は改善剤や、(3)アスパラガス擬葉を有効成分とすることを特徴とする睡眠改善剤に関する。 That is, the present invention relates to (1) an autonomic nerve regulator characterized by comprising asparagus pseudo-leaf as an active ingredient, and (2) autonomic dysfunction characterized by comprising asparagus pseudo-leaf as an active ingredient. The present invention relates to a preventive or ameliorating agent and (3) a sleep improving agent characterized by using asparagus pseudo-leaf as an active ingredient.
また、本発明は(4)アスパラガス擬葉を有効成分として含有することを特徴とする自律神経失調症の予防若しくは改善用、あるいは睡眠改善用の機能性食品又は食品素材や、(5)アスパラガス擬葉の、自律神経失調症の予防若しくは改善用、あるいは睡眠改善用の機能性食品又は食品素材の製造における使用に関する。 The present invention also includes (4) a functional food or food material for preventing or ameliorating autonomic dysfunction characterized by containing asparagus pseudo-leaf as an active ingredient, or (5) asparagus. The present invention relates to the use of gas mimetic leaves in the production of functional foods or food materials for preventing or improving autonomic dysfunction or for improving sleep.
本発明の自立神経調整剤、自律神経失調症の予防又は改善剤、睡眠改善剤、自律神経失調症の予防又は改善用機能性食品又は食品素材は、その使用において副作用がなく、また個体の感受性や嗜好性に左右されずに自律神経を鎮静的に調整でき、自律神経のバランスが崩れて交感神経が過度に優位な状態にある人たちに対して、食欲不振、高血圧、頭痛、肩こり、のぼせ、イライラなど、自律神経失調による様々な症状や、不眠症などに対して安全かつ効果的に改善することができる。また、本発明は、アスパラガス擬葉の廃棄物の有効利用と、廃棄物の軽減という面から自然環境になんら影響を及ぼすことなく、むしろエコ対策に寄与するものである。 The autonomic nerve modifier of the present invention, an agent for preventing or improving autonomic dysfunction, a sleep improving agent, a functional food or food material for preventing or improving autonomic dysfunction, has no side effects in its use, and is sensitive to individuals. It is possible to adjust the autonomic nerves statically without being influenced by taste and preference, and for those who have an excessive balance of sympathetic nerves due to the balance of the autonomic nerves, anorexia, high blood pressure, headache, stiff shoulders, hot flashes It is possible to improve safely and effectively against various symptoms caused by autonomic dysfunction such as irritation and insomnia. In addition, the present invention contributes to ecological measures without affecting the natural environment in terms of effective use of asparagus pseudo-leaf waste and reduction of waste.
本発明の自律神経調整剤、自律神経失調症の予防又は改善剤、及び睡眠改善剤としては、アスパラガスの擬葉を有効成分とするものであれば特に制限されるものではなく、上記自律神経調整剤における作用としては、疲労感、倦怠感、不眠、頭重感、発汗などの身体症状があるものの、不安感などの精神症状はあまりなく、抗不安薬を使うほどではない症状に対して改善するものであり、また、自律神経失調症には、個人差があるものの、自律神経のバランスが乱れ、自律神経系(各器官である、例えば頭、耳、口、のど、心臓・血管系、呼吸器、消化器、手、足、皮膚、泌尿器、生殖器、筋肉・関節における自律神経系)において多種類の自覚症状があり、具体的に、頭痛、耳鳴り、動悸、息詰まり、吐き気、多汗、手のしびれ、足の冷え性、頻尿、肩こり、関節の痛み、そのほか全身症状として倦怠感、疲れやすさ、めまい、のぼせ、食欲不振等の症状があり、精神症状としては、不安になる、恐怖心におそわれる、イライラする、落ち込む、怒りっぽい、集中力がない、やる気がない、記憶力や注意力が低下する症状があり、これらの症状に対して本発明は、予防又は改善するものである。また、睡眠改善剤は、眠れない、すぐ目が覚める、起きるのがつらい等の症状を改善するものである。 The autonomic nerve adjusting agent, the autonomic dysfunction prevention or improving agent, and the sleep improving agent of the present invention are not particularly limited as long as they contain an asparagus pseudo-leaf as an active ingredient. There are physical symptoms such as tiredness, fatigue, insomnia, head sensation, sweating, etc. as a function of the conditioning agent, but there are few psychological symptoms such as anxiety, and it is improved against symptoms that are not enough to use anti-anxiety drugs Although autonomic ataxia has individual differences, the balance of the autonomic nerves is disturbed, and the autonomic nervous system (each organ, such as the head, ears, mouth, throat, heart / vasculature, There are many types of subjective symptoms in the respiratory system, digestive organs, hands, feet, skin, urinary organs, genital organs, autonomic nervous system in muscles and joints), specifically headache, tinnitus, palpitation, stuffy breath, nausea, hyperhidrosis Numbness of hands, cold feet , Frequent urination, stiff shoulders, joint pain, and other general symptoms such as fatigue, ease of fatigue, dizziness, hot flashes, loss of appetite, etc. There are symptoms such as depression, anger, lack of concentration, motivation, decreased memory and attention, and the present invention prevents or improves these symptoms. The sleep improving agent improves symptoms such as inability to sleep, waking up immediately, and difficulty in getting up.
アスパラガス擬葉は、可食部の若茎が伸びた後、枝分かれしてできる茎で、葉に代わり光合成で養分を作る。露地栽培なら5、6月ごろに若茎の大半を収穫するが、翌年用に養分を根に蓄えるため一部をそのまま残し、擬葉に成長させる。本発明での利用対象は成長させることによって出現する、先端が松葉のような形をしたこの擬葉である。 Asparagus pseudo-leaf is a stalk that branches after the edible young shoots grow, and it makes nutrients by photosynthesis instead of leaves. In open-season cultivation, most of the young stems are harvested around May and June, but some are left as they are to store the nutrients in the roots for the next year and grown into pseudo leaves. The application object in the present invention is this pseudo-leaf whose tip is shaped like a pine needle, which appears by growing.
アスパラガス属植物は、ユリ科の多年草で、南ヨーロッパからウクライナが原産地であり、ヨーロッパの他、アフリカ、アジアなど広く分布している。一般に「アスパラガス」と称され、食用として利用されているものは、アスパラガス・オフィシナリス(Asparagus officinalis、和名オランダキジカクシ)であるが、その他にもA.asparagoides(クサナギカズラ)、A.cochinchinensis(クサスギカズラ)、A.plumosus(シノブボウキ)、A.myrioclaudus(タチボウキ)等が、食用、観葉、漢方などに利用されている。本発明におけるアスパラガス擬葉としては、アスパラガス・オフィシナリスの擬葉を好適に例示することができる。 Asparagus plants are perennials of the lily family, originating from southern Europe and Ukraine, and widely distributed in Europe, Africa and Asia. Asparagus officinalis, commonly referred to as "asparagus" and used as food, is also A.asparagoides (A. asparagus), A. asparagus. Cochinchinensis, A.plumosus, A.myrioclaudus, etc. are used for food, foliage, and Kampo. As an asparagus pseudo leaf in the present invention, a pseudo leaf of Asparagus officinalis can be preferably exemplified.
アスパラガスの若茎には、ルチン、サポニン、フラクトオリゴ糖や食物繊維などの機能性物質が含まれている。これらの物質の中には抗酸化作用や、抗腫瘍活性などがあることが知られている。また、アスパラガス擬葉のルチン含量は普通ソバの100〜200倍と高く、しかもソバアレルギーの心配がないことと、抹茶のようなきれいな緑色とほのかな甘味のある淡いアスパラ風味を有することから、飲食品素材として利用可能であることも知られている。 Asparagus young stems contain functional substances such as rutin, saponin, fructooligosaccharides and dietary fiber. It is known that some of these substances have an antioxidant action and an antitumor activity. In addition, the rutin content of asparagus pseudo leaves is 100 to 200 times that of ordinary buckwheat, and there is no worry of buckwheat allergy, and it has a clean green color like matcha and a light asparagus flavor with a subtle sweetness. It is also known that it can be used as a food and drink material.
本発明におけるアスパラガス擬葉には、擬葉そのものや、その処理物が含まれる。その処理物としては、アスパラガス擬葉の粉砕処理物、細断処理物、乾燥処理物、焙煎処理物、抽出処理物、超音波ホモゲナイズ処理物、凍結処理物の他、これらの処理の組み合わせにより得られる処理物を挙げることができる。例えば、アスパラガスのピューレの製造法は概略次の通りである。晩夏まで栽培して発生した擬葉を洗浄して付着している土砂、すす等を除去した後、食品用カッターにより細断し、この細断物に水を加えて電動石臼等で所定の粒度になるまで摩砕して、得られるペースト状の溶液を低温濃縮機で濃縮する。この濃縮物(ピューレ)は濃い緑色の粥状を呈し、そのままで、あるいは他の賦形剤等を配合して、本発明の自律神経調整剤、自律神経失調症の予防又は改善剤、睡眠改善剤、あるいは自律神経失調症の予防又は改善用機能性食品又食品素材として好適に利用できる。 The asparagus pseudo leaves in the present invention include the pseudo leaves themselves and processed products thereof. The processed products include asparagus pseudo leaf pulverized processed products, shredded processed products, dried processed products, roasted processed products, extracted processed products, ultrasonic homogenized processed products, frozen processed products, and combinations of these processes. The processed material obtained by this can be mentioned. For example, a method for producing asparagus puree is as follows. After removing the adhering earth and sand, soot, etc. after washing the artificial leaves that have been cultivated until late summer, shred it with a food cutter, add water to this shredded product, and use an electric stone mortar etc. The resulting pasty solution is concentrated with a low-temperature concentrator. This concentrate (pure) exhibits a dark green cocoon-like state, or as it is or in combination with other excipients, the autonomic nerve regulator of the present invention, an agent for preventing or improving autonomic dysfunction, sleep improvement It can be suitably used as an agent or a functional food or food material for preventing or improving autonomic dysfunction.
また、アスパラガス擬葉の乾燥粉砕処理物の製造法は概略次の通りである。アスパラガスの擬葉を食品用カッターにより細断し、細断された擬葉を、凍結乾燥機、減圧乾燥機、通風乾燥機などから選ばれる乾燥機を用いて温和な条件で乾燥させ、得られた乾燥アスパラガス擬葉を用途に応じた粉砕機で粉末化する。更に、例えば、ターボミル(ターボ工業株式会社)等の微粉砕機を用いて微粉末化することもできる。乾燥粉末は、そのままで、あるいは他の賦形剤等を配合して、本発明の自律神経調整剤あるいは自律神経失調症の予防又は改善剤、自律神経失調症の予防又は改善用機能性食品又は食品素材の原料として好適に利用することができる。乾燥粉末は、上記ピューレに比べて多分野での応用が可能となる。 Moreover, the manufacturing method of the dry pulverized processed product of asparagus pseudo leaves is as follows. Asparagus pseudo leaves are shredded with a food cutter, and the shredded pseudo leaves are dried under mild conditions using a dryer selected from freeze dryer, vacuum dryer, ventilation dryer, etc. The resulting dried asparagus pseudo leaves are pulverized with a pulverizer according to the application. Furthermore, it can also be finely powdered using a fine pulverizer such as a turbo mill (Turbo Industry Co., Ltd.). The dry powder can be used as it is or in combination with other excipients, the autonomic nerve regulator of the present invention or the preventive or ameliorating agent for autonomic dysfunction, a functional food for preventing or improving autonomic dysfunction, or It can be suitably used as a raw material for food materials. The dry powder can be applied in many fields as compared with the puree.
その他のアスパラガス擬葉の処理物として、アスパラガスの擬葉を細断したもの、あるいはその乾燥物、アスパラガスの擬葉を液状にしたもの(ジュース)、あるいはその乾燥物などを例示することができ、これらはそのままで、あるいは他の賦形剤等を配合して、本発明の自律神経調整剤あるいは自律神経失調症の予防又は改善剤、自律神経失調症の予防又は改善用機能性食品又は食品素材として用いることができる。 Examples of other processed asparagus pseudo leaves include those obtained by chopping pseudo asparagus pseudo leaves, or dried products thereof, liquid asparagus pseudo leaves (juice), or dry products thereof. These can be used as they are or in combination with other excipients, etc., the autonomic nerve regulator of the present invention or the preventive or ameliorating agent of autonomic dysfunction, the functional food for the prevention or improvement of autonomic dysfunction Or it can be used as a food material.
本発明の自律神経調整剤、自律神経失調症の予防又は改善剤、睡眠改善剤の剤型としては、粉剤、錠剤、カプセル剤、顆粒剤、散剤、液剤などを挙げることができ、通常サプリメントや医薬組成物として、経口的に投与する。また、これらの剤型は、従来から知られている通常の製剤方法で製造することができる。例えば、製剤の製造上許可される担体、賦形剤、香料、乳化剤、防腐剤、分散剤等と混合して成型する。また、必要に応じてさらに他の有効成分を配合することもできる。上記賦形剤の例としては、ラクトース、デキストロース、セルロース、メチルセルロース、澱粉などがあげられる。 Examples of the dosage form of the autonomic nerve adjusting agent, autonomic dystaxia preventive or ameliorating agent, and sleep improving agent of the present invention include powders, tablets, capsules, granules, powders, liquids, etc. It is administered orally as a pharmaceutical composition. Moreover, these dosage forms can be manufactured by the conventional formulation method known conventionally. For example, it is molded by mixing with carriers, excipients, fragrances, emulsifiers, preservatives, dispersants and the like that are permitted in the preparation of the preparation. Moreover, another active ingredient can also be mix | blended as needed. Examples of the excipient include lactose, dextrose, cellulose, methylcellulose, starch and the like.
本発明の自律神経失調症の予防若しくは改善用、あるいは睡眠改善用の機能性食品又は食品素材としては、アスパラガス擬葉そのものや、前記のアスパラガス擬葉の処理物を有効成分として含有し、自律神経失調症の予防若しくは改善用、あるいは睡眠改善用である点において、他のアスパラガス擬葉含有食品又は食品素材と、製品として区別しうるものであれば特に制限されず、ここで製品として区別しうる例として、食品や食品素材の包材に自律神経失調症の予防若しくは改善用、あるいは睡眠改善用の機能がある旨の表示の有無等を挙げることができる。このような機能性食品又は食品素材の製法としては、例えば、アスパラガスの擬葉を細断したもの、あるいは、その乾燥物、アスパラガスの擬葉を液状にしたもの(ピューレ、ジュース等)、あるいはその乾燥物、アスパラガスの擬葉を粉末化したものを、食品や食品素材に添加したり、或いは製造工程又は製造後に添加・配合する方法を挙げることができる。前記食品の対象としては特に制限されるものではなく、クッキー、パン、ケーキ、煎餅などの焼き菓子、ラムネ菓子等などの錠菓、羊羹などの和菓子、プリン、ゼリー、アイスクリーム類などの冷菓、チューインガム、キャンディ等の菓子類や、クラッカー、チップス等のスナック類や、うどん、そば等の麺類や、かまぼこ、ハム、魚肉ソーセージ等の魚肉練り製品や、チーズ、バターなどの乳製品や、みそ、しょう油、ドレッシング、マヨネーズ、甘味料等の調味類や、豆腐、こんにゃく、その他佃煮、餃子、コロッケ、サラダ、スープ、シチュー等の各種総菜や、ヨーグルト、ドリンクヨーグルト、ジュース、牛乳、豆乳、酒類、コーヒー、紅茶、煎茶、ウーロン茶、スポーツ飲料等の各種飲料などを具体的に例示することができる。 As a functional food or food material for preventing or ameliorating autonomic dysfunction of the present invention, or for improving sleep, asparagus pseudoleaf itself or a processed product of the asparagus pseudoleaf as an active ingredient, It is not particularly limited as long as it can be distinguished from other asparagus fake leaf-containing foods or food materials in terms of prevention or improvement of autonomic dysfunction, or sleep improvement. Examples that can be distinguished include the presence or absence of a display indicating that the food or food material packaging has a function for preventing or improving autonomic dysfunction or for improving sleep. As a method for producing such a functional food or food material, for example, chopped asparagus pseudo leaves, or dried product thereof, asparagus pseudo leaves liquefied (pure, juice, etc.), Alternatively, it is possible to add a dry product or a powdered asparagus pseudo-leaf to a food or a food material, or a method of adding and blending after a production process or after production. The food object is not particularly limited, baked confectionery such as cookies, bread, cakes, rice crackers, tablet confectionery such as ramune confectionery, Japanese confectionery such as mutton, frozen confectionery such as pudding, jelly, ice cream, Sweets such as chewing gum and candy, snacks such as crackers and chips, noodles such as udon and soba, fish paste products such as kamaboko, ham and fish sausage, dairy products such as cheese and butter, miso and soy sauce , Dressings, mayonnaise, sweeteners, and other tofu, konjac, other boiled dishes, dumplings, croquettes, salads, soups, stews, etc., yogurt, drink yogurt, juice, milk, soy milk, alcohol Specific examples include various drinks such as black tea, sencha, oolong tea, and sports drinks.
本発明の自律神経調整剤、自律神経失調症の予防又は改善剤、睡眠改善剤の投与量は、年齢、治療効果及び病態等により異なり、特に限定されないが、アスパラガスの擬葉を一日当たり乾燥重量として1〜300g、好ましくは2〜10g摂取できるよう配合量等を調整すればよい。アスパラガス擬葉は、前述のとおり、種々の剤型で、また種々の食品、飲料等に添加して服用することができるが、特に飲料の形で服用する場合は、水と共に服用すると抹茶風味となるが、好みによりスポーツ飲料、牛乳、豆乳等と共に服用してもよい。 The dosage of the autonomic nerve adjusting agent, autonomic dystaxia preventive or ameliorating agent of the present invention, sleep improving agent varies depending on age, therapeutic effect and disease state, and is not particularly limited, but the asparagus pseudo leaves are dried per day. What is necessary is just to adjust a compounding quantity etc. so that 1-300g as a weight, Preferably 2-10g can be ingested. Asparagus pseudo leaves can be taken in various dosage forms and added to various foods, beverages, etc., as described above. Especially when taking in the form of beverages, matcha flavor when taken with water. However, it may be taken together with sports drinks, milk, soy milk or the like according to preference.
以下、実施例により本発明をより具体的に説明するが、本発明の技術的範囲はこれらの例示に限定されるものではない。 EXAMPLES Hereinafter, although an Example demonstrates this invention more concretely, the technical scope of this invention is not limited to these illustrations.
(アスパラガス擬葉ピューレの調製)
収穫したアスパラガス擬葉の夾雑物を除き、洗浄後、水切りし、食品用カッター(スライサーOV型、アーシェル社製)で2〜3cmに細断した。この細断物に3倍量の水を加えて、電動石臼(マスコロイダー、増幸産業株式会社製)で、所定の粒度になるまで2回摩砕した。ペースト状の溶液を低温濃縮機(エバポール、大川原製作所製)に入れ、液温35℃、Bx15程度まで濃縮し、さらに、55℃で15分間加熱し、アスパラガス擬葉濃縮液を調製した。製品は濃い緑色の粥状を呈し、水分含有に見合うルチン、糖を含有していた。収量は150%であった。この濃縮液は、このままで、あるいは、瓶、缶、紙容器などに充填して、本発明の自律神経調整剤として使用できる。また、自律神経失調症の予防又は改善用、及び睡眠改善用として食品又は食品素材の原料として配合することができる。凍結保存も可能である。
(Preparation of asparagus pseudoleaf puree)
The harvested asparagus pseudo-leaf contaminants were removed, washed, drained, and shredded into 2 to 3 cm with a food cutter (Slicer OV type, manufactured by Archer). Three times the amount of water was added to the shredded product, and it was ground twice with an electric stone mill (mass colloider, manufactured by Masuko Sangyo Co., Ltd.) until a predetermined particle size was obtained. The paste-like solution was put into a low-temperature concentrator (Evapor, manufactured by Okawara Seisakusho), concentrated to a liquid temperature of 35 ° C. and about Bx15, and further heated at 55 ° C. for 15 minutes to prepare an asparagus pseudoleaf concentrate. The product was dark green and contained rutin and sugar suitable for water content. The yield was 150%. This concentrated solution can be used as it is, or filled in a bottle, can, paper container or the like as the autonomic nervous regulator of the present invention. Moreover, it can mix | blend as a raw material of a foodstuff or a foodstuff material for the prevention or improvement of an autonomic dysfunction, and a sleep improvement. Cryopreservation is also possible.
(アスパラガス擬葉凍結乾燥粉末の調製)
収穫したアスパラガス擬葉の夾雑物を除き、洗浄後、水切りし、食品用カッター(スライサーOV型、アーシェル社製)で2〜3cmに細断した。この細断物を−40℃で予備凍結し、さらに真空凍結乾燥機(協和真空技術(株)製)を用いて、乾燥時棚加熱温度30℃、乾燥時間48時間で凍結乾燥した。収量は24%であった。乾燥したアスパラガス擬葉をターボミル(ターボ工業株式会社)で粉砕し、粉末にした。この粉末は、このままで、あるいは、瓶、缶、紙容器などに充填して、本発明の自律神経調整剤として、また、各種剤型の自律神経調整剤に使用できる。
(Preparation of freeze-dried asparagus pseudo-leaf powder)
The harvested asparagus pseudo-leaf contaminants were removed, washed, drained, and shredded into 2 to 3 cm with a food cutter (Slicer OV type, manufactured by Archer). The shredded product was pre-frozen at −40 ° C., and further freeze-dried using a vacuum freeze dryer (manufactured by Kyowa Vacuum Technology Co., Ltd.) at a shelf heating temperature of 30 ° C. and a drying time of 48 hours. The yield was 24%. The dried asparagus pseudo leaves were pulverized with a turbo mill (Turbo Industry Co., Ltd.) to form a powder. This powder can be used as it is or filled in a bottle, a can, a paper container, or the like, as an autonomic nerve adjusting agent of the present invention, or in various dosage forms.
[顆粒(以下、配合割合は質量%で表す)]
(1)スクラロース 0.1
(2)自律神経調整剤(実施例2の乾燥粉末) 0.5
(3)香味料 5.0
(4)賦形剤(セオラス) 10.0
(5)マルチトール 残余
[Granule (Hereinafter, the blending ratio is expressed by mass%)]
(1) Sucralose 0.1
(2) Autonomic nerve regulator (dry powder of Example 2) 0.5
(3) Flavoring 5.0
(4) Excipient (Theolus) 10.0
(5) Maltitol residual
[錠剤(チュアブルタイプ)]
(1)イノシトール 11.0
(2)マルチトール 15.0
(3)スクロース 0.5
(4)鮭白子抽出物(DNA Na) 0.1
(5)酵母抽出物 0.1
(6)自律神経調整剤(実施例2の乾燥粉末) 0.5
(7)香味料 5.0
(8)賦形剤 残余
[Tablets (chewable type)]
(1) Inositol 11.0
(2) Maltitol 15.0
(3) Sucrose 0.5
(4) White coconut extract (DNA Na) 0.1
(5) Yeast extract 0.1
(6) Autonomic nerve regulator (dried powder of Example 2) 0.5
(7) Flavoring 5.0
(8) Excipient residue
[タブレット]
(1)潤沢剤(ショ糖脂肪酸エステル等) 1.0
(2)アラビアガム水溶液(5%) 2.0
(3)酸味料 1.0
(4)着色料 適量
(5)自律神経調整剤(実施例2の乾燥粉末) 1.0
(6)糖質(粉糖又はソルビトール等) 残余
[Tablet]
(1) Lubricants (sucrose fatty acid esters, etc.) 1.0
(2) Gum arabic aqueous solution (5%) 2.0
(3) Acidulant 1.0
(4) Coloring agent appropriate amount (5) Autonomic nerve modifier (dried powder of Example 2) 1.0
(6) Carbohydrate (powdered sugar or sorbitol, etc.) Residue
[キャンディー]
(1)砂糖 57.5
(2)水飴 40.0
(3)有機酸 2.0
(4)自律神経調整剤(実施例2の乾燥粉末) 0.5
[Candy]
(1) Sugar 57.5
(2) Minamata 40.0
(3) Organic acid 2.0
(4) Autonomic nerve regulator (dried powder of Example 2) 0.5
[ガム]
(1)砂糖 33.0
(2)ガムベース 30.0
(3)グルコース 10.0
(4)水飴 16.0
(5)自律神経調整剤(実施例2の乾燥粉末) 1.0
[Gum]
(1) Sugar 33.0
(2) Gum base 30.0
(3) Glucose 10.0
(4) Minamata 16.0
(5) Autonomic nerve regulator (dry powder of Example 2) 1.0
(ヒトモニター試験による睡眠改善実験)
(対象)
1)自律神経失調症状関連の医薬品を服用していない、2)試験期間中、自律神経調整剤(実施例2のアスパラガス擬葉乾燥粉末)を毎日服用し、起床時に起床時アンケートを記入できる、この2条件を満たす9名を被験者として選定した。
(試験サンプル)
試験サンプルとして、サンプルA(デキストリン)、サンプルB(自律神経調整剤:実施例2のアスパラガス擬葉乾燥粉末)の2種類を用意し、外観からはこの2種類の試験サンプルの色調が区別がつかないカプセルに、それぞれ250mg/粒となるように詰めた。
(Sleep improvement experiment by human monitor test)
(Target)
1) Do not take drugs related to autonomic dysfunction 2) During the study period, take an autonomic nerve regulator (asparagus pseudo-leaf dry powder of Example 2) every day and fill the questionnaire when waking up Nine persons satisfying these two conditions were selected as subjects.
(Test sample)
As test samples, sample A (dextrin) and sample B (autonomic nerve regulator: asparagus pseudo-leaf dry powder of Example 2) are prepared, and the color tone of these two types of test samples is distinguished from the appearance. Each unfilled capsule was packed to 250 mg / grain.
(試験方法)
乱数により2群に分けた被験者に、試験開始0日目から7日目は非服用期間として試験サンプルはなにも服用させず、8日目から21日目までは第一服用期間として試験サンプルAもしくはBを1日1回8粒、夕食後30分以内に水またはお湯で服用してもらった。試験開始22日目から28日目までは非服用期間とし、29日目から42日目までは第二服用期間として、第一服用期間で試験サンプルAを服用した被験者群には試験サンプルBを、試験サンプルBを服用した被験者群には試験サンプルAを同様の方法で服用してもらった。
試験は、被験者及びデータ解析者が、第一服用期間、第二服用期間に試験サンプルA、Bのどちらを被験者が服用したか判らないように行い、データの公平性を保った。
(Test method)
The subjects who were divided into two groups by random numbers were not allowed to take any test sample as the non-taking period from the 0th day to the 7th day of the test, and the test sample as the first taking period from the 8th day to the 21st day A or B was taken 8 times a day, with water or hot water within 30 minutes after dinner. From the 22nd to the 28th day from the start of the test, the non-taking period is set as the second taking period from the 29th to the 42nd day, and the test sample B is given to the group of subjects who took the test sample A in the first taking period. A group of subjects who took the test sample B had the test sample A taken in the same manner.
The test was performed so that the subject and the data analyst did not know whether the test sample A or B was taken by the subject during the first dose period or the second dose period, thus maintaining the fairness of the data.
就寝、起床、睡眠時間、飲酒量、服用薬物の名称及び起床時睡眠感調査表より抜粋した起床時の睡眠感に関する5項目である(1)起床時に疲れが取れている、(2)ぐっすり眠れた、(3)起床時頭がはっきりしている、(4)寝付が良かった及び(5)睡眠中に目が覚めることがなかった、について状況を記載する調査表を作成し、被験者に、試験期間中毎朝起床時直ちに状況を記入してもらった。起床時の睡眠感に関する5項目については、5段階評価の該当する箇所に○をつけてもらった。 Sleeping, getting up, sleeping time, amount of drinking, names of drugs taken, and 5 items related to the feeling of sleep when waking up, extracted from the sleep feeling survey table when waking up. (1) Getting tired when waking up. (2) Sleeping well. Create a survey table that describes the situation of (3) clear heading, (4) good sleep, and (5) did not wake up during sleep. During the test period, I was asked to fill in the situation immediately after waking up every morning. For the five items related to the feeling of sleep when waking up, ○ was given to the corresponding part of the five-step evaluation.
(服用による睡眠改善効果)
起床時の睡眠感に関する5項目についての5段階評価において、最も睡眠感が快適であった場合を10点、最も不快であった場合を−10点として期間中の睡眠感を数値化した。被験者毎に服用期間の睡眠感点数を平均した。
各被験者の睡眠感点数結果を表1に示す。
(Sleep improvement effect by taking)
In a five-stage evaluation of five items related to the feeling of sleep when waking up, the sleep feeling during the period was quantified with 10 points being the most comfortable and -10 points being the most uncomfortable. For each subject, the sleep sensation score during the dosing period was averaged.
Table 1 shows the result of sleep feeling score of each subject.
第一服用期間と第二服用期間の平均点数を比較し、有意差検定を行った。図1にサンプル毎の起床時睡眠感点数を示す。サンプルA(デキストリン)服用期間とサンプルB(自律神経調整剤)服用期間では、実施例2のアスパラガス擬葉乾燥粉末であるサンプルB服用期間で睡眠感の有意な改善が認められた(p=0.0134)。 An average score between the first and second dose periods was compared and a significant difference test was performed. FIG. 1 shows the number of sleep sensation points when waking up for each sample. In the sample A (dextrin) dosing period and sample B (autonomic nerve regulator) dosing period, a significant improvement in sleep sensation was observed in the sample B dosing period of the asparagus pseudo-leaf dry powder of Example 2 (p = 0.0134).
(症状;軽度うつ病、28歳、女性)
軽度のうつ病と診断され2年間近く薬物治療し、現在は市販パロキセチン塩酸塩20mg1錠/日にて治療中である。決められた服用量ではなく、2週間分の薬を3週間ぐらいで服用し、薬の服用を中止したいとの本人の希望もあって、アスパラガス擬葉を併用して様子をみた。アスパラガス擬葉の服用方法として、アスパラガス擬葉(実施例2の乾燥粉末)2g/日を清涼飲料水500mlに溶解懸濁させて飲用した。1週間後ぐらいで体がずいぶん楽になり、2週間を過ぎたぐらいから市販パロキセチン塩酸塩を飲むと異常にだるさ、眠気がでてきたため市販パロキセチン塩酸塩の服用を中止し経過をみた。ほぼ1ヵ月後薬の服用を完全に中止し、現在はアスパラガス擬葉と牡蠣抽出物含有錠剤6錠を服用中で回復の兆しが出てきた。
(Symptoms: Mild depression, age 28, female)
He was diagnosed with mild depression and treated for nearly 2 years. Currently, he is being treated with 20 mg / tablet of paroxetine hydrochloride on a daily basis. Instead of the prescribed dose, I took two weeks of medicine in about three weeks, and I wanted to stop taking the medicine. As a method for taking asparagus pseudo leaves, 2 g / day of asparagus pseudo leaves (dried powder of Example 2) was dissolved and suspended in 500 ml of soft drink. About one week later, my body became much easier, and after about two weeks, when I took over-the-counter paroxetine hydrochloride, I felt abnormally dull and drowsy, so I stopped taking over-the-counter paroxetine hydrochloride. The drug was completely discontinued after about a month, and now there are signs of recovery while taking 6 tablets containing asparagus fake leaves and oyster extract.
(症状;不眠、不安症、食欲不振、33歳、男性)
2年か3年前ぐらいから眠れない、急な不安感、食欲なしの症状があり、心療内科を受診し、現在、市販ミルナシプラン塩酸塩15mg2錠/日、市販ブロチゾラム1錠/日、市販クロキサゾラム1mg1錠/日を服用中で、それなりに安定しているが、日中の不安感は、まだあるためジアゼパム0.3g/日を頓服で使用していた。清涼飲料水500mlに溶解懸濁させたアスパラガス擬葉(実施例2の乾燥粉末)2g/日と市販の栄養・総合ビタミン剤4gを1日1〜2回摂取することにより、1週間後ぐらいから睡眠中に全く夢を見ることがなくなり、2週間ぐらいで自然な食欲を感じるようになってきた。アスパラガス擬葉とビタミン剤の飲用2ヶ月ぐらいで、薬をほとんど服用しないにもかかわらず、体調も睡眠状態も良好である。
(Symptoms: insomnia, anxiety, loss of appetite, 33 years old, male)
I have been unable to sleep for about 2 or 3 years, I have a sudden feeling of anxiety, no appetite, and I visited a psychosomatic medicine department. Currently, milnacipran hydrochloride 15 mg 2 tablets / day, commercially available brotizolam 1 tablet / day, commercially available Although taking cloxazolam 1 mg 1 tablet / day and being stable as such, she still had anxiety during the day, so she was taking diazepam 0.3 g / day as needed. By taking 1 g or 2 times a day of asparagus pseudo leaves (dry powder of Example 2) 2 g / day and 4 g of commercially available nutritional and multivitamin preparations dissolved and suspended in 500 ml of soft drinks, about a week later I haven't had any dreams during my sleep, so I feel a natural appetite in about two weeks. The asparagus fake leaves and vitamins have been taken for about 2 months, and the physical condition and sleep state are good even though the drug is hardly taken.
(症状;食欲不振、うつ状態、32歳、女性)
市販のフルボキサミンマレイン酸塩25mg2錠/日、市販のクロキサゾラム1mg1錠/日を服用していたが、清涼飲料水500mlに溶解懸濁させたアスパラガス擬葉(実施例2の乾燥粉末)2g/日を摂取したところ、食欲・やる気が戻り、薬を減量していき、現在は服用していない。
(Symptoms: loss of appetite, depression, age 32, female)
Commercially used fluvoxamine maleate 25 mg 2 tablets / day, commercially available cloxazolam 1 mg 1 tablet / day, but asparagus pseudo leaves (dry powder of Example 2) 2 g / day dissolved and suspended in 500 ml of soft drink When I took, I returned to my appetite and motivation, decreased my medication, and is not taking it now.
(症状;下痢、食欲不振、38歳、男性)
食欲不振、体がだるく、何もやる気がない状態であり、何らかの胃腸病であると考え、内科を受診したが異常なしと判定され、精神科を受診した。精神科の処方薬を飲んでも眠くなるだけで改善せず、毎日ERABU6錠と市販の栄養・総合ビタミン剤、漢方薬(睡眠、安定剤)6錠を併用していたものの、毎日仕事に行くのがつらく、不安に駆られる日々を過ごしていた。投薬と並行して、清涼飲料水500mlに溶解懸濁させたアスパラガス擬葉(実施例2の乾燥粉末)2g/日を服用したところ、1週間で体が楽になった。
(Symptoms: Diarrhea, loss of appetite, 38 years old, male)
Anorexia, sluggishness, lack of motivation, thought to have some kind of gastrointestinal illness. Even if you take psychiatric prescription drugs, it will only improve your sleepiness, but it will not improve. Every day you used 6 tablets of ERABU and 6 tablets of commercially available nutritional and multivitamins and herbal medicines (sleep, stabilizer). I was having a hard time in anxiety. In parallel with the administration, 2 g / day of asparagus pseudo leaves (dry powder of Example 2) dissolved and suspended in 500 ml of soft drinks was taken, and the body became comfortable in one week.
(症状;下痢、食欲不振、26歳、女性)
兄弟での会社経営によるストレスが原因となり、1日中イライラし、食欲も不振であり、体がだるく、何もする気にならない。何らかの胃腸病であると考え、内科を受診したが異常なしと判定された。しかし、どうしても1週間後の大学時代の友人たちとの富士山登山には行きたいと、この1週間は、食事は1日1食それもおかゆ程度の量をとり、それまでは、市販の栄養・総合ビタミンドリンク剤、牡蠣抽出物含有錠剤6錠などを服用していたが、登山の1週間前から、清涼飲料水500mlに溶解懸濁させたアスパラガス擬葉(実施例2の乾燥粉末)2g/日と漢方薬(牛黄精心元)3/4を追加服用したところ、すぐに食欲が出て、富士登山では、悪天候で皆が途中リタイアする中で唯一ひとり頂上まで登ることができ、元気に戻ってきた。
(Symptoms: Diarrhea, loss of appetite, age 26, female)
Due to the stress caused by the brothers' company management, they are frustrated all day, their appetite is poor, their bodies are sluggish and they don't feel like doing anything. He was diagnosed with some kind of gastrointestinal illness and visited the internal medicine department. However, if I really want to go to Mt. Fuji with my university friends a week later, this week, the meal will be about one meal a day, or about the amount of porridge. I took 6 vitamin tablets and oyster extract-containing tablets. Asparagus pseudo leaves (dried powder of Example 2) 2 g dissolved and suspended in 500 ml of soft drink from 1 week before climbing / After taking 3/4 of the day and herbal medicine (Beef Yellow Spirit), the appetite immediately emerged, and at Mt. Fuji, everyone was able to climb to the summit only when everyone retired due to bad weather. I came.
(症状;下痢、食欲不振、30歳代、男性)
下痢と腹痛、胃痛などで、胃カメラや大腸ファイバーなどの検査を受けても全く異常なしと判定された。夜も寝つきが悪く、朝はいつまでもだらだらと横になっている状態であった。市販の栄養・総合ビタミン剤と、清涼飲料水500mlに溶解懸濁させたアスパラガス擬葉(実施例2の乾燥粉末)2g/日と、市販の整腸薬3包/日とを併用したところ、1週間で元気になる。下痢も軟便になり、回数も1回ぐらいまで減少した。胃痛も薄らぎ、食欲も出てきた。夜も気がつけば寝ており、朝から食事が食べられるようになった。
(Symptoms: Diarrhea, loss of appetite, 30s, male)
Diagnosis of diarrhea, abdominal pain, stomach pain, etc., it was judged that there was no abnormality even after examination with a stomach camera or colon fiber. I had a bad sleep at night and I was lying down forever in the morning. A combination of a commercially available nutritional / multivitamin preparation, 2 g / day of asparagus pseudo-leaf (dried powder of Example 2) dissolved and suspended in 500 ml of soft drink, and 3 commercially available enteric medicines / day It will be fine in a week. Diarrhea became loose stool, and the frequency decreased to about once. My stomach ache has faded and my appetite has come out. If I noticed it at night, I went to sleep and started eating in the morning.
Claims (5)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010183967A JP4669077B1 (en) | 2009-12-28 | 2010-08-19 | Autonomic nerve regulator containing asparagus pseudo-leaf as active ingredient |
CN2011100792609A CN102370145A (en) | 2010-08-19 | 2011-03-29 | Automatic nerve regulating agent with asparagus leaf as effective ingredient |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009297659 | 2009-12-28 | ||
JP2009297659 | 2009-12-28 | ||
JP2010183967A JP4669077B1 (en) | 2009-12-28 | 2010-08-19 | Autonomic nerve regulator containing asparagus pseudo-leaf as active ingredient |
Publications (2)
Publication Number | Publication Date |
---|---|
JP4669077B1 JP4669077B1 (en) | 2011-04-13 |
JP2011153125A true JP2011153125A (en) | 2011-08-11 |
Family
ID=44021711
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010183967A Active JP4669077B1 (en) | 2009-12-28 | 2010-08-19 | Autonomic nerve regulator containing asparagus pseudo-leaf as active ingredient |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4669077B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013094676A1 (en) | 2011-12-20 | 2013-06-27 | 株式会社アミノアップ化学 | Hydroxymethylfurfural derivative |
KR20190109993A (en) * | 2018-03-19 | 2019-09-27 | 정동열 | How to make rice cakes containing asparagus and oregano extracts |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006296213A (en) * | 2005-04-15 | 2006-11-02 | Unitika Ltd | Composition obtained from asparagus |
JP2007045750A (en) * | 2005-08-10 | 2007-02-22 | Unitika Ltd | Anti-fatigue agent |
JP2009137913A (en) * | 2007-12-10 | 2009-06-25 | S Net:Kk | Lipid metabolism improver |
-
2010
- 2010-08-19 JP JP2010183967A patent/JP4669077B1/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006296213A (en) * | 2005-04-15 | 2006-11-02 | Unitika Ltd | Composition obtained from asparagus |
JP2007045750A (en) * | 2005-08-10 | 2007-02-22 | Unitika Ltd | Anti-fatigue agent |
JP2009137913A (en) * | 2007-12-10 | 2009-06-25 | S Net:Kk | Lipid metabolism improver |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013094676A1 (en) | 2011-12-20 | 2013-06-27 | 株式会社アミノアップ化学 | Hydroxymethylfurfural derivative |
US9359321B2 (en) | 2011-12-20 | 2016-06-07 | Amino Up Chemical Co., Ltd | Hydroxymethylfurfural derivative |
US9610279B2 (en) | 2011-12-20 | 2017-04-04 | Amino Up Chemical Co., Ltd. | Method for induction of a heat shock protein, anti-stress or regulation of an autonomic nerve |
KR20190109993A (en) * | 2018-03-19 | 2019-09-27 | 정동열 | How to make rice cakes containing asparagus and oregano extracts |
KR102101075B1 (en) * | 2018-03-19 | 2020-04-14 | 농업회사법인 주식회사 법화산양삼 | Rice cake manufacturing method comprising asparagus wine and perilla extract |
Also Published As
Publication number | Publication date |
---|---|
JP4669077B1 (en) | 2011-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009067731A (en) | Composition for improving cold constitution | |
KR101184666B1 (en) | Composition for improving physiological activity of positive constitution | |
KR20150051020A (en) | Composition For Anti-obesity And Diet | |
CN103857404A (en) | Agent for improving quality of sleep | |
Pérez et al. | Stevia derivative and its potential uses in diabetic-directed foods. Review | |
JP2008266223A (en) | Formulation for ameliorating excessive sensitivity to cold | |
JP7231898B2 (en) | sleep quality improver | |
JP4669077B1 (en) | Autonomic nerve regulator containing asparagus pseudo-leaf as active ingredient | |
JP7176813B2 (en) | Composition for improving fatigue | |
KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
CN110403112A (en) | A kind of preparation method of bubble orange juice | |
JP2006143664A (en) | Improving agent of indefinite complaint accompanying with autonomic imbalance | |
KR102245027B1 (en) | Composition for improving sleep disorder containing lettuce and Scutellariae extract as an active ingredient | |
CN102370145A (en) | Automatic nerve regulating agent with asparagus leaf as effective ingredient | |
JP4768105B2 (en) | Oral composition | |
CN110800893A (en) | Sucrose-free beverage with effects of reducing blood fat, reducing weight, promoting digestion, clearing heat, tonifying spleen, promoting diuresis and reducing blood sugar and preparation method thereof | |
CN110710672A (en) | Natural plant active calcium preparation and preparation method thereof | |
US20230124668A1 (en) | Psychological fatigue preventer or improver | |
JP7305595B2 (en) | Agent for improving mental fatigue, decreased motivation or drowsiness | |
JP6838752B2 (en) | Blood flow improving composition | |
KR20110124444A (en) | Composition for improving physiological activity of cold constitution | |
US20230050805A1 (en) | Autonomic nerve regulator and cognitive function improver | |
KR102478971B1 (en) | Composition for bowel movement promotion or diet | |
CN102599398B (en) | Kidney tonifying and lung-heat cleaning garden stuff nutrition congee | |
KR101477765B1 (en) | Dietary composition on the regulated and prevented of obesity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140121 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4669077 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313114 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313114 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313114 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |